Literature DB >> 1591820

ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease.

R Perondi1, A Saino, R A Tio, G Pomidossi, L Gregorini, P Alessio, A Morganti, A Zanchetti, G Mancia.   

Abstract

BACKGROUND: In humans, angiotensin converting enzyme (ACE) inhibition attenuates the vasoconstriction induced by sympathetic stimulation in a number of peripheral districts. Whether this is also the case in the coronary circulation is unknown, however. METHODS AND
RESULTS: In nine normotensive patients with angiographically assessed coronary atherosclerosis, we measured the changes in mean arterial pressure (intra-arterial catheter), heart rate, rate-pressure product (RPP), coronary sinus blood flow (CBF, thermodilution method), and coronary vascular resistance (CVR, ratio between mean arterial pressure and CBF) induced by the cold pressor test (CPT, 2 minutes) and diving (30 seconds), i.e., two stimuli eliciting a sympathetic coronary vasoconstriction. The measurements were performed in the control condition and 30 minutes after captopril 25 mg p.o. In the control condition, CPT caused an increase in mean arterial pressure and heart rate. Despite the increase in RPP (+20.7 +/- 3.2%, p less than 0.01), CBF did not change and CVR increased (+12.2 +/- 4.0%, p less than 0.05). diving caused an increase in mean arterial pressure and a reduction in heart rate. RPP increased (+14.3 +/- 3.5%, p less than 0.01), but despite this increase, there was a reduction in CBF and a marked increase in CVR (+37.3 +/- 7.4%, p less than 0.01). Captopril did not modify the blood pressure and heart rate responses to both stimuli except for a slight accentuation of the bradycardia to diving. Despite the unchanged or only slightly reduced RPP response, the increase in CVR was markedly and significantly attenuated (p less than 0.01).
CONCLUSIONS: ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. This is probably due to removal of the facilitating influence of angiotensin II on sympathetic modulation of coronary vasomotor tone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1591820     DOI: 10.1161/01.cir.85.6.2004

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

Review 1.  Angiotensin converting enzyme inhibitors in angina and myocardial infarction. What role will they play in the 1990s?

Authors:  G Ertl
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 2.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 3.  The renin-angiotensin system and coronary vasomotion.

Authors:  G Ertl; K Hu; W R Bauer; B Bauer
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 4.  Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.

Authors:  Terry K W Ma; Kevin K H Kam; Bryan P Yan; Yat-Yin Lam
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  Insulin and insulin-like growth factor I differentially induce alpha1-adrenergic receptor subtype expression in rat vascular smooth muscle cells.

Authors:  Z W Hu; X Y Shi; B B Hoffman
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

Review 6.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 7.  Effects of ACE inhibitors on coronary haemodynamics and angina pectoris.

Authors:  M K Davies
Journal:  Br Heart J       Date:  1994-09

8.  Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricular dysfunction: effects of ACE-inhibition with perindopril.

Authors:  A F van den Heuvel; P K Blanksma; H M Siebelink; L M van Wijk; F Boomsma; W Vaalburg; H J Crijns; D J van Veldhuisen
Journal:  Int J Cardiovasc Imaging       Date:  2001-10       Impact factor: 2.357

Review 9.  Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1995-09       Impact factor: 3.923

Review 10.  Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy.

Authors:  C Morisco; L Argenziano; N Tozzi; A F Mele; B Ricciardelli; G Condorelli; B Trimarco
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.